ondansetron has been researched along with Lung Adenocarcinoma in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 7.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| "The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea/vomiting (CINV) among lung cancer patients receiving multi-day chemotherapy and ondansetron- or palonosetron-initiated prophylactic antiemetic regimens in a community oncology setting." | 3.78 | Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. ( Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feinberg, B | 1 |
| Gilmore, J | 1 |
| Haislip, S | 1 |
| Jackson, J | 1 |
| Jain, G | 1 |
| Balu, S | 1 |
| Buchner, D | 1 |
1 other study available for ondansetron and Lung Adenocarcinoma
| Article | Year |
|---|---|
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Prot | 2012 |